We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Merck (MRK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
The upcoming report from Merck (MRK - Free Report) is expected to reveal quarterly earnings of $2.12 per share, indicating a decline of 17.8% compared to the year-ago period. Analysts forecast revenues of $17.23 billion, representing a decline of 0.2% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Merck metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Sales- Oncology- Alliance Revenue- Lynparza' will reach $368.98 million. The estimate indicates a year-over-year change of -2.6%.
Based on the collective assessment of analysts, 'Sales- Oncology- Keytruda' should arrive at $7.46 billion. The estimate indicates a year-over-year change of -8.4%.
The collective assessment of analysts points to an estimated 'Sales- Infectious Diseases- Zerbaxa' of $83.49 million. The estimate points to a change of +3.1% from the year-ago quarter.
The consensus estimate for 'Sales- Infectious Diseases- Prevymis' stands at $288.50 million. The estimate points to a change of +8.5% from the year-ago quarter.
The combined assessment of analysts suggests that 'Sales- Infectious Diseases- Bridion - U.S.' will likely reach $254.73 million. The estimate suggests a change of -35% year over year.
Analysts predict that the 'Sales- Oncology- Keytruda - International' will reach $3.30 billion. The estimate indicates a change of +1% from the prior-year quarter.
It is projected by analysts that the 'Sales- Diabetes- Janumet - U.S.' will reach $31.19 million. The estimate points to a change of -60% from the year-ago quarter.
The average prediction of analysts places 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' at $167.11 million. The estimate points to a change of -9.2% from the year-ago quarter.
According to the collective judgment of analysts, 'Sales- Oncology- Alliance revenue- Lynparza - International' should come in at $201.87 million. The estimate indicates a year-over-year change of +3.5%.
Analysts' assessment points toward 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' reaching $160.37 million. The estimate indicates a change of -9.4% from the prior-year quarter.
Analysts expect 'Sales- Oncology- Alliance revenue- Lenvima - International' to come in at $84.36 million. The estimate indicates a year-over-year change of +4.2%.
Analysts forecast 'Sales- Infectious Diseases- Zerbaxa - U.S.' to reach $49.99 million. The estimate indicates a change of +2% from the prior-year quarter.
Over the past month, shares of Merck have returned -2.4% versus the Zacks S&P 500 composite's -1.2% change. Currently, MRK carries a Zacks Rank #5 (Strong Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Countdown to Merck (MRK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
The upcoming report from Merck (MRK - Free Report) is expected to reveal quarterly earnings of $2.12 per share, indicating a decline of 17.8% compared to the year-ago period. Analysts forecast revenues of $17.23 billion, representing a decline of 0.2% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Merck metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Sales- Oncology- Alliance Revenue- Lynparza' will reach $368.98 million. The estimate indicates a year-over-year change of -2.6%.
Based on the collective assessment of analysts, 'Sales- Oncology- Keytruda' should arrive at $7.46 billion. The estimate indicates a year-over-year change of -8.4%.
The collective assessment of analysts points to an estimated 'Sales- Infectious Diseases- Zerbaxa' of $83.49 million. The estimate points to a change of +3.1% from the year-ago quarter.
The consensus estimate for 'Sales- Infectious Diseases- Prevymis' stands at $288.50 million. The estimate points to a change of +8.5% from the year-ago quarter.
The combined assessment of analysts suggests that 'Sales- Infectious Diseases- Bridion - U.S.' will likely reach $254.73 million. The estimate suggests a change of -35% year over year.
Analysts predict that the 'Sales- Oncology- Keytruda - International' will reach $3.30 billion. The estimate indicates a change of +1% from the prior-year quarter.
It is projected by analysts that the 'Sales- Diabetes- Janumet - U.S.' will reach $31.19 million. The estimate points to a change of -60% from the year-ago quarter.
The average prediction of analysts places 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' at $167.11 million. The estimate points to a change of -9.2% from the year-ago quarter.
According to the collective judgment of analysts, 'Sales- Oncology- Alliance revenue- Lynparza - International' should come in at $201.87 million. The estimate indicates a year-over-year change of +3.5%.
Analysts' assessment points toward 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' reaching $160.37 million. The estimate indicates a change of -9.4% from the prior-year quarter.
Analysts expect 'Sales- Oncology- Alliance revenue- Lenvima - International' to come in at $84.36 million. The estimate indicates a year-over-year change of +4.2%.
Analysts forecast 'Sales- Infectious Diseases- Zerbaxa - U.S.' to reach $49.99 million. The estimate indicates a change of +2% from the prior-year quarter.
View all Key Company Metrics for Merck here>>>Over the past month, shares of Merck have returned -2.4% versus the Zacks S&P 500 composite's -1.2% change. Currently, MRK carries a Zacks Rank #5 (Strong Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .